Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells.

Autor: Kulig P; Department of General Pathology, Pomeranian Medical University, 70-111, Szczecin, Poland.; Pharmaceutical Facility of Pomeranian Medical University, 71-899, Szczecin, Poland., Łuczkowska K; Department of General Pathology, Pomeranian Medical University, 70-111, Szczecin, Poland., Machaliński B; Department of General Pathology, Pomeranian Medical University, 70-111, Szczecin, Poland. boguslaw.machalinski@pum.edu.pl.; Department of Hematology and Transplantology, Pomeranian Medical University, 71-252, Szczecin, Poland. boguslaw.machalinski@pum.edu.pl., Baumert B; Department of Hematology and Transplantology, Pomeranian Medical University, 71-252, Szczecin, Poland. bartlomiej.baumert@pum.edu.pl.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Oct 09; Vol. 14 (1), pp. 23559. Date of Electronic Publication: 2024 Oct 09.
DOI: 10.1038/s41598-024-74558-3
Abstrakt: Lenalidomide (LEN) is widely used immunomodulatory drug (IMiD). Nonetheless, despite its efficacy, over time patients become resistant to LEN and relapse. Due to high clinical relevance, drug resistance in MM is being thoroughly investigated. However, less is known about predictors of good response to LEN-based treatment. The aim of this study was to identify molecular pathways associated with good and long response to LEN. The study included newly diagnosed MM patients (NDMM) and MM patients treated with first-line LEN and dexamethasone (RD) who achieved and least very good partial remission (VGPR). RNA was isolated from MM cells and new-generation sequencing was performed. Obtained results were validated with qRT-PCR. A global increase in gene expression was found in the RD group compared to NDMM, suggesting the involvement of epigenetic mechanisms. Moreover, upregulation of genes controlling the interaction within MM niche was detected. Next, genes controlling immune response were upregulated. In particular, the gene encoding the IL-17 receptor was overexpressed in the RD group which is a novel finding. This should be emphasized because IL-17-related signaling can potentially be targeted, providing the rationale for future research. Establishing the molecular background associated with long-lasting and profound response to LEN may improve LEN-based chemotherapy regimens and facilitate the development of adjuvant therapies to enhance its anti-MM activity.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: